CLLS Quote, Financials, Valuation and Earnings

Ascendis Pharma A/S has a net margin of 1.68% compared to Cellectis SA's net margin of -13.56%. Cellectis SA's return on equity of -31.08% beat Ascendis Pharma A/S's return on equity of -880.05%.

Cellectis SA has a consensus price target of $7.25, signalling upside risk potential of 85.9%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $282.67 which suggests that it could grow by 25.48%. Given that Cellectis SA has higher upside potential than Ascendis Pharma A/S, analysts believe Cellectis SA is more attractive than Ascendis Pharma A/S.

Cellectis SA has a beta of 2.833, which suggesting that the stock is 183.275% more volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.436, suggesting its less volatile than the S&P 500 by 56.356%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $35M, which are smaller than Ascendis Pharma A/S quarterly revenues of $288.1M. Cellectis SA's net income of $586.4K is higher than Ascendis Pharma A/S's net income of -$39.1M. Notably, Cellectis SA's price-to-earnings ratio is -- while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.85x versus 16.58x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals Plc has a net margin of 1.68% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -31.08% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

Cellectis SA has a consensus price target of $7.25, signalling upside risk potential of 85.9%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 15232.01%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Cellectis SA, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Cellectis SA.

Cellectis SA has a beta of 2.833, which suggesting that the stock is 183.275% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.469%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $35M, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Cellectis SA's net income of $586.4K is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Cellectis SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.85x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of 1.68% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -31.08% beat DBV Technologies SA's return on equity of -280.59%.

Cellectis SA has a consensus price target of $7.25, signalling upside risk potential of 85.9%. On the other hand DBV Technologies SA has an analysts' consensus of $40.16 which suggests that it could grow by 87.14%. Given that DBV Technologies SA has higher upside potential than Cellectis SA, analysts believe DBV Technologies SA is more attractive than Cellectis SA.

Cellectis SA has a beta of 2.833, which suggesting that the stock is 183.275% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $35M, which are larger than DBV Technologies SA quarterly revenues of --. Cellectis SA's net income of $586.4K is higher than DBV Technologies SA's net income of -$33M. Notably, Cellectis SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.85x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

EDAP TMS SA has a net margin of 1.68% compared to Cellectis SA's net margin of -36.13%. Cellectis SA's return on equity of -31.08% beat EDAP TMS SA's return on equity of -56.97%.

Cellectis SA has a consensus price target of $7.25, signalling upside risk potential of 85.9%. On the other hand EDAP TMS SA has an analysts' consensus of $6.83 which suggests that it could grow by 45.08%. Given that Cellectis SA has higher upside potential than EDAP TMS SA, analysts believe Cellectis SA is more attractive than EDAP TMS SA.

Cellectis SA has a beta of 2.833, which suggesting that the stock is 183.275% more volatile than S&P 500. In comparison EDAP TMS SA has a beta of -0.158, suggesting its less volatile than the S&P 500 by 115.787%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EDAP TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. EDAP TMS SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $35M, which are larger than EDAP TMS SA quarterly revenues of $16.2M. Cellectis SA's net income of $586.4K is higher than EDAP TMS SA's net income of -$5.9M. Notably, Cellectis SA's price-to-earnings ratio is -- while EDAP TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 4.85x versus 2.50x for EDAP TMS SA. Usually stocks with elevated PS ratios are considered overvalued.